“I believed in the power of PhysioPD when I first saw it twenty-five years ago, I’ve had a passion for it ever since, and now we have enough experience that I know it works.”
—Ron Beaver, PhD, Founder

About Rosa & Co

Rosa was founded in 2002 and remains an employee-owned, science-focused, and client-friendly firm. Today, Rosa is the worldwide commercial leader in PhysioPD-style Research, with comprehensive basic biology and therapeutic experience, industry-leading modeling expertise, and repeat research engagements with a majority of the Top 20 pharmaceutical companies.

Rosa Market Modeling, which offers a credible methodology for determining expected physician uptake for healthcare products, was started by Bill Brastow, Ph.D., in 2005. Our models have helped shape first-in-class markets including novel therapy combinations for HIV and molecular diagnostic tests for Oncology.

Rosa’s staff bring more than a century of aggregate experience in applying modeling to the inherent challenges faced by drug developers and have authored hundreds of scientific posters, conference presentations, relevant patents, and peer-reviewed publications.

Recent Highlights

Rosa & Co. announces the presentation of two posters at the 2021 PAGE meeting

Rosa & Co. is proud to announce that two posters authored by Rosa scientists will be presented at the upcoming Population Approach Group in Europe (PAGE) virtual meeting.Vincent Hurez, DVM, Ph.D, a Senior Scientist at Rosa & Co., will be pres... Read More

Rosa & Co. announces contributions of Dr. Christina Friedrich to the publication of an article on FDA-Industry Scientific Exchange

Rosa & Co. announced today the contributions of Dr. Christina Friedrich, Chief Engineer at Rosa, to the article titled, “FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meetin... Read More

Rosa & Co. announces the publication of an abstract in 2021 ASCO Meeting Library

Rosa & Co. announced today the publication of an abstract titled, “Modeling shows the NK3R antagonist, ACER-801, reduces treatment-induced vasomotor symptoms,” in the 2021 ASCO Meeting Library.Rosa team members Rebecca Baillie, Katherine Kurycki,... Read More

Webinar showcases how Rosa Market Modeling is used to optimize competitive positioning

Today, Rosa & Co. announced that Dr. Bill Brastow, Chief Technology Officer at Rosa Market Modeling, will present a webinar entitled “Driving Market Share for Healthcare Products by Integrating Market Modeling” on Wednesday, March 18. Hosted in p... Read More

The Rosa & Co. Executive Team